Sangamo BioSciences buys Ceregene

|About: Sangamo BioSciences, Inc. (SGMO)|By:, SA News Editor

Sangamo BioSciences (SGMO) will acquire privately held Ceregene which specializes in AAV gene therapies.

The deal gives SGMO CERE-110, a Phase 2 investigational Alzheimer's drug that contains the gene for nerve growth factor. Results are expected in 2015. (PR)